CT83 Promotes Cancer Progression by Upregulation of PDL1 in Adenocarcinoma of the Cervix

Sep 23, 2026

Uploaded by Rowan

CT83, a cancer-testis antigen, is investigated as a biomarker and therapeutic target in cervical adenocarcinoma. The study analyzes CT83 expression in cervical cancer cell lines via quantitative PCR and Western blotting, showing that CT83 overexpression increases proliferation, migration, invasion, and epithelial–mesenchymal transition while elevating PD-L1; conversely, CT83 knockdown reduces malignant phenotypes. Immunohistochemistry on 60 patient samples finds CT83 positivity in 84.9% and links higher CT83 levels (H-score ≥ 100) with larger tumors, elevated SCC, and advanced FIGO stages (II–IV). Results suggest tumor progression and immune evasion through PD-L1 modulation.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages12

Reading Time30 min

AccessFree to download

Introduction

Cancer-testis antigens and CT83 background

Rationale for targeting PD-L1 in cervical adenocarcinoma

Article CT83 Promotes Cancer Progression by Upregulation of PDL1 in Adenocarcinoma of the Cervix Gilhyang Kim 1,2, Kyung-Jun Lee 3, Eun Shin 4, Sung Taek Park 3,5, Hyeong Su Kim 3,6 and Hye-Yon Cho 3,7, * Academic Editor: Suryavathi Viswanadhapalli Received: 13 November 2024 Revised: 14 March 2025 Accepted: 16 March 2025 Published: 17 March 2025 Citation: Kim, G.; Lee, K.-J.; Shin, E.; Park, S.T.; Kim, H.S.; Cho, H.-Y. CT83 Promotes Cancer Progression by Upregulation of PDL1 in Adenocarcinoma of the Cervix. Int. J. Mol. Sci. 2025, 26, 2687. [https://](https://)[ ](https://)[doi.org/10.3390/ijms26062687](doi.org/10.3390/ijms26062687) [Copyright:](Copyright:) © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) . 1 Department of Pathology, Kangnam Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea 2 Department of Pathology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul 03181, Republic of Korea 3 Institute of New Frontier Research Team, Hallym University, Chuncheon 24252, Republic of Korea; [rudwns0222@naver.com](rudwns0222@naver.com) (K.-J.L.); [parkst96@naver.com](parkst96@naver.com) (S.T.P.); [nep2n74@gmail.com](nep2n74@gmail.com) (H.S.K.) 4 Department of Pathology, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Kyeonggido 18450, Republic of Korea; [sea4197@hallym.or.kr](sea4197@hallym.or.kr) [5](5 Department of Obstetrics and Gynecology)[ Department of Obstetrics and Gynecology](5 Department of Obstetrics and Gynecology), [Kangnam Sacred-Heart Hospital](Kangnam Sacred-Heart Hospital), [Hallym University Medical](Hallym University Medical)[ ](Hallym University Medical)Center, Hallym University College of Medicine, Seoul 07441, Republic of Korea 6 Department of Internal Medicine, Kangnam Sacred-Heart Hospital, Hallym University College of Medicine, Seoul 07441, Republic of Korea 7 Department of Obstetrics and Gynecology, Dongtan Sacred-Heart Hospital, Hallym University Medical Center, Hallym University College of Medicine, Kyeonggido 18450, Republic of Korea * [Correspondence: jugilove@gmail.com](Correspondence: jugilove@gmail.com); Tel.: +82-31-8086-2650 Abstract: CT83, a cancer-testis antigen, has emerged as a potential biomarker and therapeutic target in various cancers. This study explores its expression and role in cervical adenocarcinoma progression and prognosis. CT83 expression was analyzed in cervical cancer cell lines using quantitative PCR and Western blotting. Functional assays demonstrated that CT83 overexpression (OE) promotes proliferation, migration, invasion, and epithelial–mesenchymal transition (EMT) in cervical cancer cells while also upregulating PD-L1 expression. Conversely, CT83 knockdown reduced these malignant phenotypes. The immunohistochemical analysis of 60 patient samples revealed CT83 expression in 84.9% of cases, with significant correlations to larger tumor size, elevated squamous cell carcinoma antigen (SCC) levels, and advanced FIGO stages (II–IV) . Furthermore, intermediate-to-high CT83 expression (H-score ≥100) was associated with more aggressive disease features. These findings suggest that CT83 contributes to tumor progression and immune evasion, likely through PD-L1 modulation. As a highly expressed antigen in cervical adenocarcinoma, CT83 offers promise as a diagnostic marker and therapeutic target for improving patient outcomes. Keywords: CT83; adenocarcinoma; cervix cancer; PDL1 1. Introduction Cervical cancer is one of the most common gynecologic cancers, with an estimated 604,000 new cases and 342,000 deaths reported

FAQs

What is CT83, and why is it important in cervical adenocarcinoma?

CT83 is a cancer-testis antigen described as emerging as a potential biomarker and therapeutic target. In this study, it is examined for its role in cervical adenocarcinoma progression and prognosis.

How does CT83 affect cervical cancer cell behavior?

CT83 overexpression promotes proliferation, migration, invasion, and epithelial–mesenchymal transition, and it increases PD-L1 expression. CT83 knockdown reduces these malignant phenotypes.

What patient data support the clinical relevance of CT83?

Immunohistochemistry on 60 patient samples shows CT83 expression in 84.9% of cases. Intermediate-to-high CT83 expression (H-score ≥ 100) correlates with larger tumor size, higher SCC levels, and advanced FIGO stages (II–IV).

Sep 23, 2026

Uploaded by Rowan